Crisil affirmed it's A- long-term rating and A2+ short-term rating on PPAP Automotive' (NSE:PPAP, BOM:532934) bank loan facilities, according to a Friday stock exchange filing.
The rating outlook is stable, the filing said.
Related Articles
Asia
Netwealth's FUA Net Flows in Fiscal Q4 Likely to See Seasonal Step-up, Jarden Says
Netwealth Group's (ASX:NWL) funds under administration (FUA) net flows are likely to see a seasonal step-up in the fiscal fourth quarter, which would see the fiscal 2026 outcome tracking slightly ahead of its guidance range, Jarden said in a Thursday note.It raised its earnings-per-share forecasts by 0.1% for fiscal 2026, 1.5% for fiscal 2027, and 1.6% for fiscal 2028.Jarden also flagged the risk of higher cost growth due to the enforceable undertaking, regulatory scrutiny, and recent treasury consultations.The investment firm retained its neutral recommendation on Netwealth Group and raised the price target to AU$25.70 from AU$25.35.Netwealth Group's shares gained 1% in recent Friday trade.
ASX:NWL
Asia
CDL Hospitality REIT Issues Stapled Securities as Payment of Management Fee
CDL Hospitality REIT (SGX:J85) issued 5.5 million stapled securities to its manager, H-REIT Manager and HBT Trustee-Manager as payment of management fee for 2025, according to a Friday filing with the Singapore Exchange.Nearly 5 million stapled securities were issued to the H-REIT Manager at SG$0.8199 per security as 80% payment of its performance fee for 2025.Meanwhile, 535,179 securities were issued to HBT Trustee-Manager at SG$0.8199 per security as payment of 80% of performance fee for 2025.
SGX:J85
Asia
Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says
Syntara's (ASX:SNT) Amsulostat drug candidate has a "unique" position in the myelofibrosis landscape and "significant" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a blood cancer characterized by scar tissue formation or fibrosis in the bone marrow.Dr Adam Craig, Syntara strategic adviser and an industry leader in myelofibrosis, noted Amsulostat's mechanism targeting fibrosis, with the potential as a disease-modifying therapy, rather than just a symptomatic treatment.Craig said that Amsulostat's safety profile differs from current therapies and is unaware of any other drug taking a similar approach.Additionally, Craig said that Amsulostat's mechanism requires time for effect, as fibrosis evolves gradually. Patient responses observed at six months are complemented by a continuing improvement over time.Euroz Hartleys reaffirmed its speculative buy recommendation and AU$0.22 price target on Syntara.Syntara shares fell 1% in afternoon trade on Friday.
ASX:SNT